LGVN News and Press, Longeveron Inc. From 07/10/24

2024-07-10 11:38:21 ET Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration. Lomecel-B is the company’s investigational treatment for Alzheimer’s disease. Longeveron stock is st...

A look at the top 10 most actives in the United States Longeveron Inc. (LGVN) rose 69.0% to $4.8499 on volume of 46,980,986 shares Virpax Pharmaceuticals Inc. (VRPX) rose 161.5% to $3.0333 on volume of 46,199,502 shares Maxeon Solar Technologies Ltd. (MAXN) fell 0.6% to $0.2464 on volume ...

2024-07-10 09:53:04 ET More on Longeveron Longeveron Inc. (LGVN) Q1 2024 Earnings Call Transcript Longeveron announces exercise of warrants for $4.4M gross proceeds Longeveron announces launch of contract development and manufacturing business Seeking Alpha&#...

MIAMI, July 10, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for certain life-threatening and chronic aging-related conditions, today announced that the U.S. Food and Drug Administration (...

A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) rose 2.5% to $131.38 on volume of 280,159,738 shares Maxeon Solar Technologies Ltd. (MAXN) fell 8.1% to $0.248 on volume of 217,585,873 shares Tesla Inc. (TSLA) rose 3.7% to $262.33 on volume of 159,323,492 s...

A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) fell 9.3% to $0.2448 on volume of 58,139,351 shares NVIDIA Corporation (NVDA) rose 2.9% to $131.9 on volume of 38,975,630 shares Soligenix Inc. (SNGX) rose 189.2% to $5.784 on volume of 36,915,609...

MIAMI, July 09, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, including hypoplastic left heart syndrome (HLHS) and Alzheimer&#...

Longeveron (NASDAQ: LGVN) , a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has appointed Roger Hajjar, MD, director of the Gene and Cell Therapy Institute at Mass General Brigham, to its board o...

MIAMI, July 08, 2024 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Roger Hajjar , MD, Director of the Gene and...

2024-06-28 16:24:47 ET More on Longeveron Longeveron announces exercise of warrants for $4.4M gross proceeds Longeveron announces launch of contract development and manufacturing business Read the full article on Seeking Alpha For further details see: Lon...